Open label extension (OLE) data from the PALISADE trial of plozasiran in genetic or clinical familial chylomicronaemia syndrome (FCS) and the ARCHES-2 trial of zodasiran in mixed hyperlipidaemia have confirmed the efficacy and safety profiles of the two agents.
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
